TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV

Sponsor
Aktion Bronchialkarzinom e.V.
Study ID
NCT01674738
Phase
PHASE2
Status
Withdrawn

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Pemetrexed — DRUG
    500 mg/m2 i.v. on day 1 (three-week cycle)
  • Cisplatin — DRUG
    75 mg/m2 i.v. on day 1 (three-week cycle)
  • Bevacizumab — DRUG
    7,5 mg/kg i.v. on day 1 (three-week cycle)

Study Details

This study wants to determine the activity of a first-line treatment related to Thymidylate Synthetase (TS) Expression. Patients with the diagnosis of non-squamous advanced Non-Small-Cell Lung-Cancer (Stage IV) and without evidence of EGFR mutation may be enclosed in this clinical trial.

Key Dates

First listed
Aug 29, 2012
Status verified
Oct 2013

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Pemetrexed, Cisplatin, Bevacizumab
    Stratum A
  • Experimental: Pemetrexed, Cisplatin, Bevazizumab
    Stratum B:

Primary Outcome Measure

Progression free survival [ Time Frame: Recruitment period 1,5 years, observation period 2 years ]

Related Studies